Skip to content

Advertisement

Acta Neuropathologica Communications

Research
Open Access

Two alternative pathways for generating transmissible prion disease de novo

Acta Neuropathologica Communications20153:69

https://doi.org/10.1186/s40478-015-0248-5

©  Makarava et al. 2015

Received: 8 September 2015

Accepted: 27 October 2015

Published: 10 November 2015

Abstract

Introduction

Previous studies established that prion disease with unique strain-specific phenotypes could be induced by in vitro-formed recombinant PrP (rPrP) fibrils with structures different from that of authentic prions, or PrPSc. To explain the etiology of prion diseases, new mechanism proposed that in animals the transition from rPrP fibrils to PrPSc consists of two main steps: the first involves fibril-induced formation of atypical PrPres, a self-replicating but clinically silent state, and the second consists of atypical PrPres-dependent formation of PrPSc via rare deformed templating events.

Results

In the current study, atypical PrPres with characteristics similar to those of brain-derived atypical PrPres was generated in vitro. Upon inoculation into animals, in vitro-generated atypical PrPres gave rise to PrPSc and prion disease with a phenotype similar to those induced by rPrP fibrils. Significant differences in the sialylation pattern between atypical PrPres and PrPSc suggested that only a small sub-fraction of the PrPC that is acceptable as a substrate for PrPSc could be also recruited by atypical PrPres. This can explain why atypical PrPres replicates slower than PrPSc and why PrPSc outcompetes atypical PrPres.

Conclusions

This study illustrates that transmissible prion diseases with very similar disease phenotypes could be produced via two alternative procedures: direct inoculation of recombinant PrP amyloid fibrils or in vitro-produced atypical PrPres. Moreover, this work showed that preparations of atypical PrPres free of PrPSc can give rise to transmissible diseases in wild type animals and that atypical PrPres generated in vitro is an adequate model for brain-derived atypical PrPres.

Keywords

Prion DiseaseScrapieProtein Misfolding Cyclic AmplificationAtypical Bovine Spongiform EncephalopathySimilar Disease Phenotype

Introduction

Prions are proteinaceous infectious agents that are underlying causes of fatal neurodegenerative diseases known as prion diseases or transmissible spongiform encephalopathies (TSE) [1]. Prions consist of misfolded, aggregated states of the normal, cellular form of the prion protein (PrPC). Prion diseases can arise spontaneously, be inherited or be acquired through transmission [1]. Prions spread between organisms or from cell to cell by replicating their disease-specific misfolded structures via a template-assisted mechanism [2]. This mechanism postulates that PrPSc template recruits and converts PrPC expressed by a host into PrPSc. According to this mechanism, the folding pattern of a newly formed PrPSc accurately replicates that of the PrPSc template, and prion replication exhibits high fidelity [2].

Recent studies demonstrated that in the presence of certain cellular components such as RNA and/or lipids, highly pure recombinant PrP converts into authentic PrPSc conformations in vitro that can effectively induce transmissible prion diseases in animals [3–6]. At the same time, transmissible prion disease could also be induced by recombinant PrP (rPrP) amyloid fibrils formed in vitro in the absence of any co-factors although at low efficiency [7–12]. Bearing in mind that the structures of rPrP fibrils produced in vitro were found to be fundamentally different from that of PrPSc [13, 14], these studies raised the possibility that an unexplored mechanism responsible for the etiology of prion diseases exists [15, 16]. According to this mechanism, referred to as deformed templating, a self-replicating state with one folding pattern can seed structurally different self-replicating states with alternative folding patterns when exposed to a new replication environment [16]. The newly generated self-replicating states that fit well to the new environment outcompete the original template. A new replication environment might include, but is not limited to, new biochemical or cellular conditions, a new substrate with altered amino acid sequence or posttranslational modifications, or presence of prion inhibitors [17–22]. In direct support of the deformed templating mechanism, molecular imaging revealed that switching between alternative folding patterns can occur within individual PrP amyloid fibrils when amyloid seeds were exposed to heterologous substrate in vitro [23]. In another illustration of the deformed templating mechanism, novel, structurally altered self-replicating PrPSc states that were absent in the original seeding material emerged upon changes to the biochemical environment, which involved a depletion of RNA from protein cyclic amplification reactions and subsequent addition of RNA to the reactions [17]. In addition, upon change in pH, non-infectious fibrils of recombinant fungal prion protein HET-s with a stacked β-sheet architecture gave rise to the alternative, infectious state of HET fibrils with a β-solenoid structure [24].

Previous studies proposed that evolution of authentic PrPSc from rPrP fibrils consists of two main steps [11, 12] (Fig. 1). The first step involves formation of atypical PrPres, a self-replicating state that is triggered in animals upon inoculation of rPrP fibrils. While atypical PrPres is transmissible, it is clinically silent and not neurotoxic [25]. In a second step, atypical PrPres give rise to PrPSc in rare deformed templating events that are believed to be stochastic in nature. Because atypical PrPres and PrPSc are significantly different in structure [11, 12, 26, 27], a transition from the former to the latter is believed to represent the major barrier to the evolution of authentic PrPSc.
Figure 1
Fig. 1

Schematic illustration of two alternative pathways for generating PrPSc. The first pathway was established in previous studies [11, 12], it involves direct inoculation of in vitro-generated rPrP fibrils into animals and consists of two main steps. In a first step, rPrP fibrils seeded atypical PrPres, a transmissible form of PrP that replicates silently without causing clinical disease. In a second step, atypical PrPres produces PrPSc in rare and stochastic seeding events that are described by a deformed templating mechanism [16]. PrPSc replicates faster than atypical PrPres and eventually replaces it during serial passages. An alternative pathway is under investigation by the current work. In vitro-generated rPrP fibrils were used to seed serial dgPMCAb that produced fibril-induced atypical PrPres, which was inoculated into animals

The current work is inspired by recent findings that atypical PrPres with characteristics similar to those of brain-derived atypical PrPres can be generated in vitro by seeding Protein Misfolding Cyclic Amplification reactions with beads (PMCAb) using rPrP fibrils (Fig. 1). Three questions have been asked in the current work. The first is whether atypical PrPres generated in vitro gives a rise to PrPSc and prion disease in animals (Fig. 1). The second is whether the strain-specific disease phenotype associated with in vitro-generated atypical PrPres is similar to those of synthetic strains produced by direct inoculation of animals by rPrP fibrils. The third is whether evolution of authentic PrPSc and development of prion diseases can be accelerated if the first of the two main steps, i.e. formation of atypical PrPres, is accomplished in vitro.

Materials and methods

Expression and purification of rPrP and formation of rPrP fibrils

Syrian hamster full-length rPrP encompassing residues 23–231 was expressed and purified according to a previously described procedure [28] with minor modifications [10]. Lyophilized rPrP was dissolved in 5 mM HEPES, pH 7.0, immediately before use. To form fibrils, a mixture of 0.5 mg/ml rPrP with 50 mM MES, pH 6.0, and 2.0 M or 0.5 M guanidine hydrochloride (GdnHCl) was incubated at 37 °C under continuous agitation. Amyloid formation was confirmed by thioflavin T fluorescence assay as described previously [28]. Fibrils were dialyzed against 10 mM sodium acetate, pH 5.0 for storage. If required, fibrils were heat-treated in PBS, pH 7.4 in the presence of 5 mg/ml BSA (Sigma, Cat. #A3294) or 5 % brain homogenate prepared from healthy hamsters (see below) as described before [10, 29].

Preparation of 10 % brain homogenate (BH)

10 % (wt/vol) brain homogenates were prepared in PBS, pH 7.4, using glass/Teflon homogenizers attached to a cordless 12 V compact drill (Ryobi) as previously described [30].

Protein misfolding cyclic amplification with beads (PMCAb)

10 % normal brain homogenate (NBH) from healthy hamsters was prepared as described previously [12] and used as a substrate for PMCAb [31]. For the first round, 10 μl of water-diluted rPrP fibrils were added to 90 μl of NBH resulting in the 5 μg/ml final rPrP concentration in the reaction. For the reactions seeded with brain-derived PrPSc, 10 μl of scrapie BH from inoculated animals were diluted in PBS to achieve the desired final concentration and added to 90 μl of NBH. The standard sonication program consisted of 20 s sonication pulses at ~150 W applied every 20 min during a 24 h period. For each subsequent round, 10 μl of the reaction from the previous round were added to 90 μl of fresh substrate. Each PMCAb reaction was carried out in the presence of two 3/32” Teflon beads (amazonsupply.com). To analyze production of PK-resistant PrP material in PMCAb, 10 μl of sample were supplemented with 5 μl of SDS and 5 μl of PK to a final concentration of SDS and PK of 0.25 % and 50 μg/ml, respectively, followed by incubation at 37 °C for 1 h. The digestion was terminated by addition of SDS-sample buffer and heating the samples for 10 min in a boiling water bath.

Protein misfolding cyclic amplification with partially deglycosylated substrate (dgPMCAb) and generation of atypical PrPres in vitro

To produce substrate for dgPMCAb, 10 % NBH from healthy hamsters prepared for PMCAb was treated with peptide-N-glycosidase F (PNGase F) (New England BioLabs, glycerol-free) as follows. After preclearance of NBH at 500 × g for 2 min, 1500 U/ml PNGase F was added to the supernatant, and the reaction was incubated on a rotator at 37 °C for 5 h. The resulting substrate was used in dgPMCAb with sonication conditions described for PMCAb. To produce brain-derived atypical PrPres, dgPMCA substrate was treated with RNase A (Sigma, catalog no. R4875) for 1 h at 37 °C as described previously [32], and seeded with 109-fold diluted brain material of the animal from the second passage of synthetic strain S05 [11], which contained predominantly atypical PrPres. dgPMCAb was carried out for 18 rounds with 10-fold dilution between rounds. The absence of PrPSc in the final product was confirmed by failure to amplify in 6 rounds of PMCAb (Fig. 2d).
Figure 2
Fig. 2

Generating rPrP fibril-induced atypical PrPres in dgPMCAb. a Analysis of PK-resistant materials produced in 6th round of serial PMCAb or dgPMCAb reactions seeded with four preparations of rPrP fibrils or non-seeded reactions by Western blot. F2M or F0.5 are fibrils generated in 2 M or 0.5 M GdnHCl, respectively, as previously described [11]. FBSA or FNBH are fibrils annealed in BSA or NBH as previously described [10, 29]. b Analysis of PK-resistant materials produced in 6th round of serial dgPMCAb reactions seeded with four independent preparations of F0.5 fibrils or non-seeded reactions by Western blot. c Establishing a limiting dilution for atypical PrPres in S05 brain material. S05 brain material was subjected to 10-fold serial dilutions for up to 1013-fold and used for seeding serial dgPMCAb, using a procedure previously described [34]. Western blot analysis of 18th serial dgPMCA rounds demonstrates that 109-fold diluted S05 brain material was the last dilution that contained atypical PrPres material. d To confirm that preparation of brain-derived atypical PrPres subjected to 18th dgPMCA rounds lacks PrPSc, serial PMCAb reactions were seeded with the products of 18th dgPMCAb round or 109-fold diluted S05 brain material, then subjected to six serial PMCAb rounds and analyzed by Western blot. PK-resistant bands at 23, 16 and 13 kDa represent di-, mono- and unglycosylated atypical PrPres, respectively. Western blots in panels a-c were stained with SAF-84 antibody and in panel d with 3F4 antibody

Bioassay

Each hamster received 50 μl of inoculum intracerebrally, under 2 % O2/4 minimum alveolar concentration (MAC) isoflurane anesthesia. After inoculation, animals were observed daily for disease using a ‘blind’ scoring protocol. The study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The animal protocol was approved by the Institutional Animal Care and Use Committee of the University of Maryland, Baltimore (Assurance Number A32000-01; Permit Number: 0215002).

Proteinase K digestion of brain homogenates

For the PK digestion in sarcosyl, an aliquot of 10 % BH was prepared as described previously [30]. Briefly, 10 % BH was mixed with an equal volume of 4 % sarcosyl in PBS, supplemented with 50 mM Tris, pH 7.5, and digested with 20 μg/ml PK (New England BioLabs) for 30 min at 37 °C with 1000 rpm shaking using a DELFIA plate shaker (Wallac) placed in 37 °C incubator. PK digestion was stopped by adding SDS sample buffer and heating the samples for 10 min in a boiling water bath. Samples were loaded onto NuPAGE 12 % Bis-Tris gels, transferred to PVDF membrane, and probed with 3F4 or SAF-84 antibodies.

Analysis of conformational stability and Proteinase K resistance

10 % brain homogenate was diluted 10 times into PMCAb conversion buffer, then supplemented with an equal volume of GdnHCl solution in PBS to a final concentration of GdnHCl ranging from 0.4 to 4 M, and incubated at room temperature for 1 h. Next, nine volumes of 2 % sarkosyl in PBS were added to all samples followed by 1 h incubation at room temperature, and then the samples were treated with 20 μg/mL PK for 1 h at 37 °C with shaking. The digestion was stopped with 2 mM PMSF, and the proteins were precipitated in four volumes of ice-cold acetone, incubated overnight at −20 °C, and subsequently centrifuged for 30 min at 16000 x g. Pellets were dried for 30 min, resuspended in 1 × SDS-sample buffer, loaded into NuPAGE 12 % bisTris gels, then transferred to PVDF membrane, and stained with 3F4 or SAF-84 antibody. To analyze PK resistance, 10 % BH was diluted 10-fold into PMCAb conversion buffer, then supplemented with 0.2 % SDS and digested with serially diluted glycerol-free PK (Sigma, Cat. # P6556) for 1 h at 37 °C. The digestion was terminated by addition of SDS-sample buffer and heating the samples for 10 min in a boiling water bath.

PNGase F treatment of PrPSc

10 % brain homogenate was diluted with an equal volume of 4 % sarcosyl in PBS, pH 7.4, digested with 20 μg/ml PK as described above, deglycosylated following the procedure described previously [10], and assayed by Western blot with 3 F4 antibody.

2D electrophoresis

25 μL samples were heated for 10 min in a boiling water bath in the presence of gel loading buffer, solubilized for 1 h at room temperature with 200 μL solubilization buffer (8 M Urea, 2 % (wt/vol) CHAPS, 5 mM TBP, 20 mM TrisHCl pH 8.0), then alkylated by adding 7 μL of 0.5 M iodoacetamide and incubated for 1 h at room temperature in the dark. Then, 1150 μL of ice-cold methanol was added and samples were incubated for 2 h at −20 °C. After centrifugation at 16,000 g at 4 °C, supernatant was discarded and the pellet was re-solubilized in 160 μL rehydration buffer (7 M urea, 2 M thiourea, 1 % (wt/vol) DTT, 1 % (wt/vol) CHAPS, 1 % (wt/vol) Triton X-100, 1 % (vol/vol) ampholyte, trace amount of Bromophenol Blue). Fixed immobilized pre-cast IPG strips (cat. # ZM0011, Life Technologies, Carlsbad, CA) with a linear pH gradient 3–10 were rehydrated in 155 μL of resulting mixture overnight at room temperature inside IPG Runner cassettes (cat. # ZM0008, Life Technologies). Isoelectrofocusing (first dimension separation) was performed at room temperature with rising voltage (175 V for 15 min, then 175–2,000 V linear gradient for 45 min, then 2,000 V for 30 min) on Life Technologies Zoom Dual Power Supply using the XCell SureLock Mini-Cell Electrophoresis System (cat. # EI0001, Life Technologies). The IPG strips were then equilibrated for 15 min consecutively in (i) 6 M Urea, 20 % (vol/vol) glycerol, 2 % SDS, 375 mM Tris-HCl pH 8.8, 130 mM DTT, and (ii) 6 M Urea, 20 % (vol/vol) glycerol, 2 % SDS, 375 mM Tris-HCl pH 8.8, 135 mM iodoacetamide, and loaded on 4–12 % Bis-Tris ZOOM SDS-PAGE pre-cast gels (cat. # NP0330BOX, Life Technologies). For the second dimension, SDS-PAGE was performed for 1 h at 170 V. Immunoblotting was performed as described elsewhere, blots were stained using 3F4 or SAF-84 antibody.

Histopathological study

The brains of two animals from the second passage of F0.5-derived atypical PrPres were evaluated for the presence of spongiform changes and intensity of PrP immunostaining. Formalin-fixed brain halves divided at the midline (left hemisphere) were processed for hematoxylin-eosin (H&E) stain and immunohistochemistry staining using the mouse monoclonal anti-PrP antibody 3F4 (1:1000, Covance). Blocks were treated in formic acid (96 %) before being embedded in paraffin. For detection of disease-associated PrP, blocks were pretreated by 15 min hydrated autoclaving at 121 °C in trisodium citrate buffer, pH 6.0 with 0.05 % Tween 20, followed by 5 min in 88 % formic acid.

Results

Triggering atypical PrPres in vitro is a generic property of rPrP fibrils

In previous studies, upon inoculations into animals, rPrP fibrils were shown to induce misfolding of PrPC into atypical PrPres [11, 12]. To test whether this process could be recapitulated in vitro, rPrP fibrils were prepared according to the protocols used in previous studies for making fibrils that induced transmissible prion diseases [10–12, 29]. Regardless of the experimental protocol, all fibril preparations triggered atypical PrPres in a PMCAb format that used partially deglycosylated PrPC substrate, referred to as dgPMCAb (Fig. 2a) [26]. Notably, dgPMCAb was previously found to favor selective replication of brain-derived atypical PrPres over PrPSc [26]. When serial PMCAb reactions, instead of dgPMCAb, were seeded with the same fibril preparations, no PK-resistant products were found (Fig. 2a). This result is in agreement with the previous studies that rPrP fibrils do not seed PrPSc nor contain small amounts of PrPSc amplifiable by PMCAb [11, 12, 33]. rPrP fibril-induced formation of atypical PrPres in dgPMCAb was robust and highly reproducible (Fig. 1b). No PK-resistant products were found in non-seeded dgPMCAb control reactions (Fig. 1b). For further experiments, we choose rPrP fibrils prepared in 0.5 M GdnHCl (abbreviated as F0.5), as they were the most effective in inducing prion disease in animals [11].

In vitro preparation of atypical PrPres materials for animal bioassay

To prepare atypical PrPres for inoculation, dgPMCAb reactions were seeded with F0.5 fibrils and subjected to ten serial rounds. The products of the 10th rounds, abbreviated as F0.5-induced atypical PrPres, were inoculated into Syrian hamsters. In parallel to the F0.5-induced atypical PrPres, brain-derived atypical PrPres material free of PrPSc was also produced for inoculation using the following strategy. When subjected to a serial dgPMCAb, atypical PrPres readily amplifies, whereas PrPSc does not. To ensure the absence of PrPSc the following procedures were followed. First, S05 brain material of an asymptomatic animal containing predominantly atypical PrPres was used to seed dgPMCAb [11]. Second, for seeding, this material was diluted 109-fold that corresponds to the limiting dilution of atypical PrPres (Fig. 1c) (dgPMCAb titration of atypical PrPres material is in Additional file 1: Figure S1). Third, the substrate for dgPMCAb was treated with RNase, a procedure that selectively amplifies atypical PrPres but not PrPSc [26]. Fourth, 18 serial dgPMCAb rounds with 10-fold dilutions between rounds were conducted to completely dilute out any initial PrPSc material, if such would still present after the initial 109-fold dilution (Fig. 2c). Moreover, to confirm absence of PrPSc in the preparation of brain-derived atypical PrPres amplified in dgPMCAb, the products of the 18th dgPMCAb round were subjected to six serial PMCAb rounds (Fig. 2d). Previously, we showed that six PMCAb rounds were sufficient for amplifying a single PrPSc particle to the amounts detectible by Western blot [34]. As expected, no PrPSc was detected by Western blot after six PMCAb rounds in the preparation of atypical PrPres (Fig. 2d).

F0.5-induced atypical PrPres propagates in vivo and gives rise to PrPSc

F0.5-induced atypical PrPres as well as S05 brain-derived atypical PrPres amplified in dgPMCAb were inoculated into two groups of wild type animals to test whether atypical PrPres is able to give rise to PrPSc (Table 1, Fig. 2). The results of these inoculations were compared to the direct inoculation of F0.5 fibrils (Table 1). In addition, S05 brain material, used to seed dgPMCAb for production of brain-derived atypical PrPres, was also inoculated after dilution to 0.3 % to match the amount of atypical PrPres, after 18 rounds of dgPMCAb (Table 1). Two out of ten animals inoculated with F0.5-induced atypical PrPres were sacrificed at 441 days post inoculation. Atypical PrPres was found in their brains, proving that fibril-derived atypical PrPres generated in vitro is able to propagate in vivo (Fig. 3a). Because PK-resistant bands of atypical PrPres and PrPSc overlap (Fig. 3b), discrimination between the two forms required staining with 3F4 (detects only PrPSc) and SAF-84 (stains both PrPSc and atypical PrPres). While no PrPSc was found by Western blot at 441 days post inoculation (Fig. 3a), serial PMCAb revealed that small amounts of PrPSc were present in brains of these animals (Fig. 3c). Later on, at 476 days postinoculation, one out of eight animals remaining in this group developed clinical signs similar to those previously observed for synthetic hamster strains. The disease progressed very slowly just like the slow progression in hamsters inoculated with other synthetic strains [11, 12, 30]. This animal was euthanized 582 days postinoculation. In addition to atypical PrPres, PrPSc was detected by Western blot in the brain of the symptomatic animal (Fig. 3a). The remaining, asymptomatic animals were euthanized between 606 and 636 days postinoculation (Table 1). None of the animals from the other groups showed clinical disease, albeit atypical PrPres and PrPSc were found in animals of all groups. In summary, animal bioassay proved that atypical PrPres generated in vitro by seeding dgPMCAb with rPrP fibrils replicated in vivo and gave rise to PrPSc.
Table 1

Bioassay of rPrP amyloid fibrils

Inoculum

ns/nt a

nPKres/nt b

Euthanized, days post inocul.

F0.5 rPrP fibrils (1st passage)

0/7

6/7

723

F0.5 fibril-induced atypical PrPres (1st passage)

1/10

10/10

2 at 441, 582, 2 at 630, 5 at 636

Brain-derived atypical PrPres amplified in dgPMCA

0/4

4/4

606

atypical PrPres from S05 brainc

0/4

4/4

606

BH from animal inoculated with F0.5 fibril-induced atypical PrPres (2nd passage)

4/6

6/6

630

a number of animals with clinical signs over the total number of animals survived to the end of the experiment

b number of animals with PK-resistant PrP in BHs detectible by Western blot over the total number of animals survived to the end of the experiment

c 0.3 % brain material from the second passage of SO5 [11]

Figure 3
Fig. 3

Analysis of brain materials from the first passage. a Western blots of brain materials from animals inoculated with F0.5-induced atypical PrPres and sacrificed at 441 days post-inoculation. Brain material from animal inoculated directly with F0.5 is included as a reference. b Schematic representation of the PK resistance profile showing overlap between atypical PrPres and PrPSc, where atypical PrPres and PrPSc are represented by gray and black boxes, respectively. c Western blot analysis of PK-resistant materials amplified in serial PMCAb reactions seeded with brain materials from animals inoculated with F0.5-induced atypical PrPres and sacrificed at 441 days. d Western blots of brain materials from animals inoculated with F0.5 fibrils, F0.5 fibril-induced atypical PrPres, 0.3 % S05 brain material or brain-derived atypical PrPres prepared as described in Fig. 2c. Western blots were stained with SAF-84 or 3F4 antibody as indicated

Transition from atypical PrPres to PrPSc and a competition between atypical PrPres and PrPSc

To elucidate relationship between atypical PrPres and PrPSc, the relative amounts of two states were compared by Western blot in four groups: animals inoculated with F0.5 fibrils, F0.5-induced atypical PrPres, S05 brain-derived atypical PrPres amplified in dgPMCAb, and with diluted S05 brain material not subjected to dgPMCA (Fig. 3b, d). Several observations could be made. First, atypical PrPres were found in all animals from all four groups, whereas PrPSc were observed only in a fraction of animals and in smaller amounts than atypical PrPres (Fig. 3d). Such dynamics support the hypothesis that atypical PrPres is the first product of PrPC misfolding, that it faithfully propagates in vivo independently of PrPSc and that it precedes PrPSc. Second, small amounts of PrPSc detectible by Western blot were found in the brains of animals infected with the preparations of brain-derived atypical PrPres amplified in dgPMCAb that lacked PrPSc. This result suggests that atypical PrPres not only precedes, but also gives rise to PrPSc. Not surprisingly, the highest amounts of PrPSc were found in the group inoculated with S05 brain material, since in addition to atypical PrPres it contained small amount of PrPSc. Brain-derived atypical PrPres enriched through dgPMCA lacked PrPSc and thus resulted in formation of very low amounts of PrPSc upon inoculation, similar to the amount of PrPSc found in the brains inoculated with F0.5-induced atypical PrPres. Interestingly, without the interference of PrPSc, atypical PrPres accumulated to a greater degree. Unexpectedly, PrPSc amounts accumulated in the brains of animals inoculated with F0.5 fibril-induced or brain-derived atypical PrPres did not exceed the amount of PrPSc found in some animals inoculated with F0.5 fibrils. This observation, however, is consistent with the two-step mechanism, according to which (i) atypical PrPres gives rise to PrPSc in a stochastic manner and (ii) PrPSc competes with atypical PrPres (Fig. 1). As judged from PK-resistance and conformational stability assays, both PrPSc and atypical PrPres were extremely resistant to PK degradation and GdnHCl-induced denaturation (Additional file 2: Figure S2). Such high conformational stability and stability to proteolytic degradation explains why both states can co-exist and compete with each other for a long time. Upon inoculation of high amounts of preformed atypical PrPres, PrPSc arises, but has a low chance of outcompeting atypical PrPres in the 1st passage.

Atypical PrPres and PrPSc are structurally different

Previous work established that atypical PrPres and PrPSc have different structures, based on different the length of the PK-resistant core, glycoform ratios and different RNA-dependency for amplification [11, 12, 26, 27]. The predominantly monoglycosylated composition of atypical PrPres suggests that the diglycosylated glycoforms are excluded from atypical PrPres, presumably due to strong structural constraints and electrostatic repulsion between negatively charged terminal sialic acid residues on N-linked glycans. Assuming that structural constraints are much stronger in atypical PrPres than PrPSc, we propose that diglycosylated, hypersialylated molecules should be selectively excluded in atypical PrPres. To test this hypothesis, distribution of charge isoforms that reflects sialylation patterns of individual PrP molecules within PrPSc or atypical PrPres were analyzed using 2D (Fig. 4) [35]. In both states, unglycosylated molecules showed more than one charge isoforms (Fig. 4). This charge heterogeneity is largely attributed to the structural heterogeneity of the GPI anchors [36]. As expected, in PrPSc the distribution of monoglycosylated isoforms extended into acidic pH far beyond that of unglycosylated isoforms, and the distribution of diglycosylated isoforms extended into acidic pH beyond monoglycosylated isoforms (Fig 4a). This is because diglycosylated isoforms can incorporate more sialic acid residues per molecule than monoglycosylated isoforms. In atypical PrPres, the distribution of monoglycosylated isoforms also extended into acidic pH far beyond that of unglycosylated isoforms (Fig. 4b). However, diglycosylated isoforms did not extend beyond monoglycosylated isoforms, illustrating that atypical PrPres excluded diglycosylated molecules with high sialylation levels. Atypical PrPres of three different origins were compared by 2D: one induced in animals by inoculating F0.5 fibrils, atypical PrPres induced by inoculating brain-derived atypical PrPres amplified in dgPMCAb, and atypical PrPres from asymptomatic S05 animals [11]. They all showed very similar if not identical sialylation patterns characterized by the absence of hypersialylated diglycosylated molecules, a pattern that was notably different from that of PrPSc (Fig. 4).
Figure 4
Fig. 4

2D analysis of sialylation status of PrPSc and atypical PrPres. 2D analysis of charge distribution of S05 brain-derived PrPSc (a) and atypical PrPres from animals inoculated with F0.5 fibrils (b, upper panel), atypical PrPres induced in animals by inoculating brain-derived atypical PrPres amplified in dgPMCAb (b, middle panel), or asymptomatic S05 animals that lacked PrPSc (b, lower panel). Black triangles, white triangles and arrows mark di-, mono-, and unglycosylated glycoforms, respectively. The distributions of all three glycoforms of atypical PrPres are shifted toward acidic pH relative to those of PrPSc due to differences in number of charged amino acid residues and, accordingly, pIs between atypical PrPres and PrPSc. All samples were treated with PK. Western blots were stained with 3F4 (a) and SAF-84 (b)

Two alternative biochemical pathways produce synthetic strains with similar disease phenotype

Next, we tested whether in vitro-generated atypical PrPres results in a disease phenotype similar to those previously described for the synthetic strains triggered by inoculation of rPrP fibrils directly. Brain material from the animal inoculated with F0.5-induced atypical PrPres and euthanized at 441 days post inoculation was used for the second passage. Using animal euthanized at the early time point allowed initiating the second passage approximately 200 days before the remaining animals from this group were euthanized. In the second passage, clinical disease was observed in 4 out of 6 animals after 500 dpi (Table 1). In agreement with the slow disease progression of synthetic hamster strains described previously [11, 12], the clinical disease here progressed very slowly. Animals approached terminal stages approximately 120 days after the first clinical signs and were euthanized at 630 days due to the old age. Animals displayed the same set of clinical symptoms including rough coat, dry skin and obesity as was previously observed for the synthetic strains [10–12].

Consistent with TSE, histopathological analysis of animals from the second passage revealed a high degree of spongiform vacuolation in multiple brain areas including cerebellum, cortex, caudoputamen and thalamus (Fig. 5). Diffuse, synaptic PrP immunoreactivity was observed in the aforementioned subregions (Fig. 5). Large PrPSc plaques were observed in the periventricular subependymal region (Fig. 6), which is a hallmark of hamster synthetic strains including S05 [11]. Perineuronal PrP deposits were found in the thalamus, basal ganglia, and deeper layers of the cortex (Fig. 6). Overall, the type and brain regions of PrP depositions were consistent with depositions observed in the second passage of S05 strain produced upon direct inoculation of F0.5 fibrils [11].
Figure 5
Fig. 5

Histopathological analysis. Spongioform changes stained with hematoxylin and eosine (upper panels) or PrP deposisiton stained with 3F4 antibody (lower panels) in hippocampus, thalamus, cerebellum, frontal cortex or caudoputamen in animals from the second passage of F0.5-induced atypical PrPres that developed clinical disease. Scale bars = 200 μm

Figure 6
Fig. 6

Plaques, perineuronal, perivascular or diffuse PrP depositions. PrP immunoreactivity stained with 3F4 antibody in subependymal (a), subpial (b), cerebellum white matter (c), or deeper layer of cortex (d) in animals from the second passage of F0.5-induced atypical PrPres that developed clinical disease. Red arrows point at perivascular deposition in c or perineuronal deposition in d. Scale bars = 50 μm

Analysis of brain material from the 2nd passage of F0.5-induced atypical PrPres revealed increased accumulation of PrPSc, in addition to propagation of atypical PrPres (Fig. 7a). The dynamics between atypical PrPres and PrPSc were very similar to those observed during serial passaging of S05 strain that was produced upon inoculation of F0.5 fibrils directly. In the second passage of F0.5 the amounts of PrPSc increased while atypical PrPres was still able to replicate (Fig. 7b). For S05, the amounts of PrPSc formed in the course of the second passage were variable and depended on the ratio of PrPSc to atypical in the inoculums (Fig. 7b). The dynamics between the two forms is consistent with the hypothesis that the two forms compete with each other and that PrPSc replaces atypical PrPres over time.
Figure 7
Fig. 7

Dynamics between atypical PrPres and PrPSc in animals from the first and second passages. a Western blots of brain materials from animals of the first and second passages of F0.5-induced atypical PrPres. Brain material from an animal of the second passage of F0.5 (S05) included as a reference. b Western blots of brain materials from animals of the first, second and third passages of F0.5 fibrils. Arrows indicate animals that were used for preparing inoculums for the subsequent passages. Western blots were stained with SAF-84 or 3F4 antibody as indicated. c Brain materials from 263K- or S05-inoculated animals or second passage of F0.5 fibrils were treated with PNGase and PK, analyzed by Western blot and stained with 3F4

PNGase treatment revealed that the sizes of the PK-resistant cores were the same for PrPSc from the second passages of F0.5-induced atypical PrPres and the second passage of S05, both of which were ~0.5-1 kDa shorter than that of the 263K strain (Fig. 7c). In summary, the disease phenotype observed in a second passage of F0.5-induced atypical PrPres was very similar, if not identical to, that described in previous studies for S05 [11].

Discussion

The results in the current study are important for the following reasons. First, this work illustrates that transmissible prion disease with very similar if not identical disease phenotypes can be generated via two experimental procedures that utilize alternative biochemical pathways. The initial step of both pathways involves an in vitro conversion of rPrP into an amyloid fibrilar state. However, the first procedure involves direct inoculation of rPrP fibrils into animals, whereas the second protocol relies on production of atypical PrPres in vitro in reactions seeded with rPrP fibrils. Second, this study provides the first direct illustration that preparations of atypical PrPres free of PrPSc produced transmissible diseases when inoculated into wild type animals. Atypical PrPres is a self-replicating, transmissible, but clinically silent state. Third, the current work provides strong support for the mechanism established in previous studies and presented in Fig. 1 that atypical PrPres is an alternative transmissible state, which is also a precursor of PrPSc [11, 12]. Fourth, the current study demonstrates that atypical PrPres generated in vitro using dgPMCAb is an adequate model for atypical PrPres formed in brain. Indeed, inoculation of in vitro-generated F0.5-induced atypical PrPres led to the de novo formation of atypical PrPres in animals. Moreover, both F0.5-induced atypical PrPres and brain-derived atypical PrPres gave rise to PrPSc upon serial transmission. In both atypical PrPres states, F0.5-induced and brain-derived, monoglycosylated PrP was the predominant glycoform and hypersialylated diglycosylated isoforms were missing. This is in contrast to the glycosylation pattern of all currently known hamster strains of synthetic or natural origin, in which diglycosylated PrP is the predominant glycoform [37]. In support of previous studies, this work argues that atypical PrPres can be faithfully and selectively propagated in the dgPMCAb [26].

The mechanism in Fig. 1 postulates that evolution of synthetic prions involves two main steps. Completing the first step, which involved a transition from rPrP fibrils to atypical PrPres, in vitro instead of in vivo did not accelerate the disease development. This result suggests that the major barrier on a pathway toward PrPSc is associated with the second step, i.e. generation of PrPSc via deformed templating events, which are believed to be rare and stochastic. The data on the dynamics between the two forms suggest that atypical PrPres and PrPSc compete with each other (Figs. 3 and 7). Atypical PrPres gives rise to PrPSc in stochastic events that might occur earlier or later in the course of infection. In experiments where the first PrPSc arises from atypical PrPres before a critical amount of atypical PrPres is accumulated, PrPSc is able to propagate efficiently and rapidly replaces atypical PrPres (Fig. 3d). If PrPSc appears later in the course of the infection when the amount of atypical is above a certain threshold, PrPSc replication is slowed down. Inoculation of atypical PrPres material, which was selectively amplified in dgPMCA and free of PrPSc, proved its ability to produce PrPSc in animals. However, it also provided a selective advantage to the propagation of atypical PrPres conformations. Under such inoculation conditions, PrPSc accumulation during the first passage was very weak. Several passages might be needed for the PrPSc to rich a level, at which it exceed and effectively outcompete atypical PrPres as it was observed with S05 [11]. With the atypical PrPres inhibiting propagation of the disease-related forms we have an interesting case of a “protective misfolding”, where PrPC recruitment into an alternative misfolded, PK-resistant, non-toxic, self-replicating state delays development of a deadly disease.

Atypical PrPres is remarkable with respect to its biochemical and biological properties. While fully transmissible in animal studies, this is a clinically silent state, which in the absence of PrPSc does not cause prion diseases or clinical symptoms [11, 12, 25]. Atypical PrPres forms large plaques and diffuse synaptic oligomers, however, neither is associated with neurotoxic or pathogenic effects [25]. Atypical PrPres is structurally different from PrPSc, as evident from the differences in length of PK-resistant fragments, glycoform ratios and RNA-dependency of their amplification in vitro [11, 12, 26, 27]. Moreover, the current study established that atypical PrPres and PrPSc exhibit significantly different sialylation patterns. In accordance with previous work [35], PrPSc was found to contain PrP molecules with a wide range of sialylation levels encompassing molecules with both highly and moderately sialylated glycans. In contrast to PrPSc, atypical PrPres does not recruit PrPC with high levels of sialylation. Negatively charged sialic acid residues create electrostatic repulsion between neighboring N-linked glycans. Differences in sialylation status suggest that atypical PrPres has much stronger structural constraints for recruiting diglycosylated or heavily sialylated molecules than PrPSc. As a result, only a fraction of PrPC that is acceptable as a substrate for PrPSc is also acceptable to atypical PrPres. Differences in sialylation offer one of the possible explanations why atypical PrPres replicates slower than PrPSc and why PrPSc can eventually outcompete atypical PrPres. Differences in sialylation pattern could also be responsible for the lack of toxicity by atypical PrPres. This hypothesis remains to be tested. Alternatively, the lack of neurotoxicity could be due to the absence of structural determinants associated with toxic effects. Another hypothesis that would be interesting to consider in future studies is whether sialylation deficiency observed in certain genetic or metabolic disorders can facilitate conversion of PrPC into alternative self-replicating states similar to atypical PrPres or CTF12/13 associated with sCJD.

A number of atypical or short PK-resistant fragments has been identified in human and animal prion diseases. PK-resistant fragments referred to as CTF12/13 that encompass residues 154/156-231 and 162/167-231 were found in the majority of patients with sCJD [38]. C-terminal PK-resistant species of similar size were also found in iatrogenic CJD [39] and in mice infected with mouse-passaged hamster scrapie [40]. Furthermore, similar C-terminal PK-resistant fragments were found in atypical bovine spongiform encephalopathy, which is believed to be sporadic in origin [41], and in certain types of ovine scrapie [42]. While the size and position of PK-resistant fragments of atypical PrPres described in the current study are very similar to those found in human and animal diseases of natural origin, it is not clear whether they are structurally related or play similar role in disease etiology. Moreover, the relationship of the C-terminal fragments found in sCJD, iatrogenic CJD or in atypical bovine spongiform encephalopathy to PrPSc is also uncertain. Taking into account results presented here, one can speculate that CTF12/13 species are precursors of PrPSc and important for the etiology of sporadic CJD. Testing this hypothesis would involve selective amplification of sCJD-derived CTF12/13 species in dgPMCAb to generate CTF12/13 material free of PrPSc and then testing whether this material induce prion diseases with sCJD phenotype in humanized mice. Comparison of the sialylation status of atypical PK resistant fragments in prion diseases of natural and synthetic origin would help to establish a relationship between them as well as their relationship with PrPSc.

This work highlights the role of deformed templating in transformation and evolution of protein self-replicating states. The deformed templating model predicts emergence of new, structurally altered self-replicating states upon changes in replication environment [16]. In agreement with this prediction, treatments with anti-prion drugs or prion inhibitors were found to result in transformation of strain-specific properties and emergence of drug-resistant prions [20, 43–45].

Conclusions

In summary, the current work illustrate for the first time that transmissible prion disease with similar disease phenotype can be produced via two alternative procedures: direct inoculation of recombinant PrP amyloid fibrils or in vitro-produced atypical PrPres. Moreover, this work showed that preparations of atypical PrPres free of PrPSc can give rise to transmissible diseases in wild type animals and that atypical PrPres generated in vitro is an adequate model for brain-derived atypical PrPres. Finally, the current study illustrates a remarkable case of competition between two transmissible states formed by the same protein, where one state being clinically silent, whereas another being neurotoxic and responsible for progression of disease. Differences in sialylation patterns between PrPSc and atypical PrPres revealed that only a fraction of PrPC that is acceptable as a substrate for PrPSc is also acceptable to atypical PrPres. This explains why atypical PrPres replicates slower than PrPSc and why PrPSc can eventually outcompete atypical PrPres. Other amyloidogenic proteins that are responsible for a range of neurodegenerative disease are known to spread via prion-like mechanisms [46, 47]. It remains to be determined whether competition between clinically silent and toxic states is a general phenomenon or specific to the prion protein.

Abbreviations

BSA: 

bovine serum albumin

sCJD: 

sporadic Creutzfeldt Jakob Disease

dgPMCAb: 

Protein misfolding cyclic amplification with partially deglycosylated substrate

dpi: 

days post inoculation

GdnHCl: 

Guanidine Hydrochloride

NBH: 

Normal brain homogenate

PBS: 

Phosphate buffered saline buffer

PK: 

Proteinase K

PMCAb: 

Protein misfolding cyclic amplification with beads

PNGase F: 

peptide-N-glycosidase F

PrPC : 

normal, cellular form of the prion protein

PrPSc : 

disease-associate, infectious form of the prion protein

rPrP: 

recombinant prion protein

TSEs: 

Transmissible Spongiform Encephalopathies

Declarations

Acknowledgments

We thank Pamela Wright for editing the manuscript. Financial support for this study was provided by National Institute of Health Grants R01 NS045585 and R01 NS074998.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Center for Biomedical Engineering and Technology, University of Maryland School of Medicine, Baltimore, USA
(2)
Department of Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, USA

References

  1. Prusiner SB. Prion diseases and the BSE crisis. Science. 1997;278:245–51.View ArticlePubMedGoogle Scholar
  2. Cohen FE, Prusiner SB. Pathologic conformations of prion proteins. Annu Rev Biochem. 1998;67:793–819.View ArticlePubMedGoogle Scholar
  3. Wang F, Wang X, Yuan CG, Ma J. Generating a Prion Bacterially Expressed Recombinant Prion Protein. Science. 2010;327:1132–5.PubMed CentralView ArticlePubMedGoogle Scholar
  4. Zhang Z, Zhang Y, Wang F, Wang X, Xu Y, Yang H, et al. De novo generation of infectious prions with bacterially expressed recombinant prion protein. Faseb J. 2013;27:4768–75.PubMed CentralView ArticlePubMedGoogle Scholar
  5. Deleault NR, Piro JR, Walsh DJ, Wang F, Ma J, Geoghegan JC, et al. Isolation of phosphatidylethanolamine as a solitary cofactor for prion formation in the absence of nucleic acids. Proc Acad Natl Sci U S A. 2012;109:8546–51.View ArticleGoogle Scholar
  6. Deleault NR, Walsh DJ, Piro JR, Wang F, Wang X, Ma J, et al. Cofactor molecules maintain infectious conformation and restrict strain properties in purified prions. ProcAcadNatlSciUSA. 2012;109:E1938–46.View ArticleGoogle Scholar
  7. Legname G, Baskakov IV, Nguyen HOB, Riesner D, Cohen FE, DeArmond SJ, et al. Synthetic mammalian prions. Science. 2004;305:673–6.View ArticlePubMedGoogle Scholar
  8. Colby DW, Giles K, Legname G, Wille H, Baskakov IV, DeArmond SJ, et al. Design and construction of diverse mammalian prion strains. ProcAcadNatlSciUSA. 2009;106:20417–22.View ArticleGoogle Scholar
  9. Colby DW, Wain R, Baskakov IV, Legname G, Palmer CG, Nguyen HO, et al. Protease-sensitive synthetic prions. PLoS Pathogen. 2010;6:e1000736.View ArticleGoogle Scholar
  10. Makarava N, Kovacs GG, Bocharova OV, Savtchenko R, Alexeeva I, Budka H, et al. Recombinant prion protein induces a new transmissible prion disease in wild type animals. Acta Neuropathol. 2010;119:177–87.PubMed CentralView ArticlePubMedGoogle Scholar
  11. Makarava N, Kovacs GG, Savtchenko R, Alexeeva I, Ostapchenko VG, Budka H, et al. A New Mechanism for Transmissible Prion Diseases. J Neurosci. 2012;32:7345–55.PubMed CentralView ArticlePubMedGoogle Scholar
  12. Makarava N, Kovacs GG, Savtchenko R, Alexeeva I, Budka H, Rohwer RG, et al. Genesis of mammalian prions: from non-infectious amyloid fibrils to a transmissible prion disease. PLoS Pathogen. 2011;7:e1002419.View ArticleGoogle Scholar
  13. Wille H, Bian W, McDonald M, Kendall A, Colby DW, Bloch L, et al. Natural and synthetic prion structure from X-ray fiber diffraction. ProcAcadNatlSciUSA. 2009;106:16990–5.View ArticleGoogle Scholar
  14. Ostapchenko VG, Sawaya MR, Makarava N, Savtchenko R, Nilsson KP, Eisenberg D, et al. Two amyloid states of the prion protein display significantly different folding patterns. J Mol Biol. 2010;400:908–21.PubMed CentralView ArticlePubMedGoogle Scholar
  15. Makarava N, Baskakov IV. Genesis of transmissible protein states vie deformed templating. Prion. 2012;6:252–5.PubMed CentralView ArticlePubMedGoogle Scholar
  16. Makarava N, Baskakov IV. The Evolution of Transmissible Prions: The Role of Deformed Templating. PLOS Pathog. 2013;9:e1003759.PubMed CentralView ArticlePubMedGoogle Scholar
  17. Gonzalez-Montalban N, Lee YJ, Makarava N, Savtchenko R, Baskakov IV. Changes in prion replication environemnt cause prion strain mutation. Faseb J. 2013;27:3702–10.PubMed CentralView ArticlePubMedGoogle Scholar
  18. Ghaemmaghami S, Watts JC, Nquyen HO, Hayashi S, DeArmond SJ, Prusiner SB. Conformational transformation and selection of synthetic prion strains. J Mol Biol. 2011;413:527–42.PubMed CentralView ArticlePubMedGoogle Scholar
  19. Ghaemmaghami S, Colby DW, Nquyen HO, Hayashi S, Oehler A, DeArmond S, et al. Convergent Replication of Mouse Synthetic Prion Strains. Am J Pathol. 2013;182:866–74.PubMed CentralView ArticlePubMedGoogle Scholar
  20. Berry DB, Lu D, Geva M, Watts JC, Bhardwaj S, Oehler A, et al. Drug resistance confounding prion therapeutics. Proc Acad Natl Sci USA. 2013;110:E4160–9.View ArticleGoogle Scholar
  21. Mahal SP, Jablonski J, Suponitsky-Kroyter I, Orlschlegel AM, Herva ME, Oldstone M, et al. Propagating of RML prions in mice expressing PrP devoid of GPI anchor leads to formation of a novel, stable prion strain. PLOS Pathog. 2012;8:e1002746.PubMed CentralView ArticlePubMedGoogle Scholar
  22. Cancellotti E, Mahal SP, Somerville R, Diack A, Brown D, Piccardo P, et al. Post-translational changes to PrP alter transmissible spongiform encephalopathy strain properties. EMBO J. 2013;32:756–69.PubMed CentralView ArticlePubMedGoogle Scholar
  23. Makarava N, Ostapchenko VG, Savtchenko R, Baskakov IV. Conformational switching within individual amyloid fibrils. J Biol Chem. 2009;284:14386–95.PubMed CentralView ArticlePubMedGoogle Scholar
  24. Wan W, Bian W, McDonald M, Kijac A, Wemmer DE, Stubbs G. Heterogeneous Seeding of a Prion Structure by a Generic Amyloid Form of the Fungal Prion-forming Domain HET-s(218–289). J Biol Chem. 2013;288:29604–12.PubMed CentralView ArticlePubMedGoogle Scholar
  25. Kovacs GG, Makarava N, Savtchenko R, Baskakov IV. Atypical and classical forms of the disease-associated state of the prion protein exhibit distinct neuronal tropism, deposition patterns, and lesion profiles. Am J Pathol. 2013;183:1539–47.PubMed CentralView ArticlePubMedGoogle Scholar
  26. Makarava N, Savtchenko R, Baskakov IV. Selective amplification of classical and atypical prions using modified protein misfolding cyclic amplification. J Biol Chem. 2013;288:33–41.PubMed CentralView ArticlePubMedGoogle Scholar
  27. Klimova N, Makarava N, Baskakov IV (2015) The diversity and relationship of prion protein self-replicating states. Virus Research in press.Google Scholar
  28. Bocharova OV, Breydo L, Parfenov AS, Salnikov VV, Baskakov IV. In vitro conversion of full length mammalian prion protein produces amyloid form with physical property of PrPSc. JMolBiol. 2005;346:645–59.Google Scholar
  29. Bocharova OV, Makarava N, Breydo L, Anderson M, Salnikov VV, Baskakov IV. Annealing PrP amyloid firbils at high temperature results in extension of a proteinase K resistant core. J Biol Chem. 2006;281:2373–9.View ArticlePubMedGoogle Scholar
  30. Makarava N, Kovacs GG, Savtchenko R, Alexeeva I, Budka H, Rohwer RG, et al. Stabilization of a prion strain of synthetic origin requires multiple serial passages. J Biol Chem. 2012;287:30205–14.PubMed CentralView ArticlePubMedGoogle Scholar
  31. Gonzalez-Montalban N, Makarava N, Ostapchenko VG, Savtchenko R, Alexeeva I, Rohwer RG, et al. Highly Efficient Protein Misfolding Cyclic Amplification. PLoS Pathogen. 2011;7:e1001277.View ArticleGoogle Scholar
  32. Gonzalez-Montalban N, Makarava N, Savtchenko R, Baskakov IV. Relationship between Conformational Stability and Amplification Efficiency of Prions. Biochemistry. 2011;50:7933–40.PubMed CentralView ArticlePubMedGoogle Scholar
  33. Piro JR, Wang F, Walsh DJ, Rees JR, Ma J, Supattapone S. Seeding Specificity and Ultrastructural Characteristics of Infectious Recombinant Prions. Biochemistry. 2011;50:7111–6.PubMed CentralView ArticlePubMedGoogle Scholar
  34. Makarava N, Savtchenko R, Alexeeva I, Rohwer RG, Baskakov IV. Fast and ultrasensitive method for quantitating prion infectivity titer. Nature Commun. 2012;3:741.View ArticleGoogle Scholar
  35. Katorcha E, Makarava N, Savtchenko R, D’Azzo A, Baskakov IV. Sialylation of prion protein controls the rate of prion amplification, the cross-species barrier, the ratio of PrPSc glycoform and prion infectivity. PLOS Pathog. 2014;10:e1004366.PubMed CentralView ArticlePubMedGoogle Scholar
  36. Stahl N, Baldwin MA, Hecker R, Pan KM, Burlingame AL, Prusiner SB. Glycosylinositol phospholipid anchors of the scrapie and cellular prion proteins contain sialic acid. Biochemistry. 1992;31:5043–53.View ArticlePubMedGoogle Scholar
  37. Nishina K, Deleault NR, Mahal S, Baskakov I, Luhrs T, Riek R, et al. The Stoichiometry of Host PrPC Glycoforms Modulates the Efficiency of PrPSc formation in vitro. Biochemistry. 2006;45:14129–39.View ArticlePubMedGoogle Scholar
  38. Zou WQ, Capellari S, Parchi P, Sy MS, Gambetti P, Chen SG. Identification of Novel Proteinase K-resistant C-terminal Fragments of PrP in Creutzfeldt-Jakob Disease. J Biol Chem. 2003;278:40429–36.View ArticlePubMedGoogle Scholar
  39. Satoh K, Muramoto T, Tanaka T, Kitamoto N, Ironside JW, Nagashima K, et al. Association of an 11–12 kDa protease-resistant prion protein fragment with subtypes of dura graft-associated Creutzfeldt-Jakob disease and other prion diseases. J Gen Virol. 2003;84:2885–93.View ArticlePubMedGoogle Scholar
  40. Lawson VA, Priola SA, Meade-White K, Lawton M, Chesebro B. Flexible N-terminal region of prion protein influences conformation of protease resistant prion protein isoforms associated with cross-species scrapie infection in vivo and in vitro. J Biol Chem. 2004;279:13689–95.View ArticlePubMedGoogle Scholar
  41. Biacabe AG, Jacobs JG, Bencsik A, Langeveld JP, Baron TG. H-type bovine spongiform encephalopathy: complex molecular features and similarities with human prion diseases. Prion. 2007;1:61–8.PubMed CentralView ArticlePubMedGoogle Scholar
  42. Baron T, Bencsik A, Vulin J, Biacabe AG, Morignat E, Verchere J, et al. A C-terminal protease-resistant prion fragment distinguishes ovine “CH1641-like” scrapie from bovine classical and L-Type BSE in ovine transgenic mice. PLOS Pathog. 2008;4:e1000137.PubMed CentralView ArticlePubMedGoogle Scholar
  43. Li J, Browning S, Mahal SP, Oelschlegel AM, Weissmann C. Darwinian evolution of prions in cell culture. Science. 2010;327:869–72.PubMed CentralView ArticlePubMedGoogle Scholar
  44. Giles K, Berry DB, Condello C, Hawley RC, Gallardo-Godoy A, Bryant C, et al. (2015) Different 2-aminothiazole therapeutics produce distinct patterns of scrapie prion neuropathology in mouse brains. J Pharmacol Exp Ther in press.Google Scholar
  45. Oelschlegel AM, Weissmann C. Acquisition of Drug Resistance and Dependence by Prions. PLOS Pathog. 2013;9:e1003158.PubMed CentralView ArticlePubMedGoogle Scholar
  46. Soto C, Estrada L, Castilla J. Amyloids, prions and the inherent infectious nature of misfolded protein aggregates. Trends BiochemSci. 2006;31:150–5.View ArticleGoogle Scholar
  47. Walker LC, Jucker M. Neurodegenerative Diseases: Expanding the Prion Concept. Annu Rev Neurosci. 2015;38:87–103.View ArticlePubMedGoogle Scholar

Copyright

© Makarava et al. 2015

Advertisement

Acta Neuropathologica Communications

ISSN: 2051-5960

Contact us